More News
19 February 2014
BioAtla Grants BioMotiv Exclusive Worldwide Rights to IL-22 Antibody for Inflammatory Bowel Diseases and Colorectal Cancer18 February 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction18 February 2014
Novimmune Announces Closing of CHF 60 Million Financing17 February 2014
Oxford BioMedica and Sanofi Amend Terms for Ocular Licence17 February 2014
Kissei Announces Business Collaboration Agreement with Alteogen14 February 2014
Nestlé Skin Health Is Created Targeting Global Skin Health Needs14 February 2014
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib14 February 2014
Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine13 February 2014
Immuno-oncology : licensing agreement between Aurigene and Pierre Fabre Pharmaceuticals13 February 2014
€85 Million European Programme Targets Novel Antibiotics11 February 2014
Debiopharm Group™ to Acquire Affinium’s Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics11 February 2014
MEDIMMUNE ANNOUNCES RESEARCH COLLABORATION WITH UC SAN FRANCISCO11 February 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash10 February 2014
Audion Announces Investment and Licensing Deal With Lilly To Develop Hearing Loss Treatments10 February 2014
Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes6 February 2014
Zosano Pharma Enters into a License Agreement with Novo Nordisk to Deliver Semaglutide Using Zosano’s Microneedle Patch System5 February 2014
Ichor Enters into an Agreement with Pfizer to Develop Electroporation Devices for Use in Therapeutic Cancer Vaccine Regimens5 February 2014
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-34755 February 2014
Novo Nordisk – Innate Pharma acquires full rights to anti-NKG2A checkpoint inhibitor from Novo Nordisk5 February 2014
Domain Therapeutics enters into collaboration with XOMANews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports